Dietary phosphate restriction in dialysis patients: A new approach for the treatment of hyperphosphataemia

被引:15
|
作者
Guida, B. [1 ]
Piccoli, A. [2 ]
Trio, R. [1 ]
Laccetti, R. [1 ]
Nastasi, A. [1 ]
Paglione, A. [1 ]
Memoli, A. [3 ]
Memoli, B. [3 ]
机构
[1] Univ Naples Federico II, Physiol Nutr Unit, Dept Neurosci, Naples, Italy
[2] Univ Padua, Dept Med & Surg Sci, I-35100 Padua, Italy
[3] Univ Naples Federico II, Div Nephrol, Naples, Italy
关键词
Dietary phosphate; Hyperphosphataemia; Dialysis; CHRONIC-RENAL-FAILURE; HEMODIALYSIS-PATIENTS; MAINTENANCE HEMODIALYSIS; MINERAL METABOLISM; PROTEIN INTAKE; PHOSPHORUS; DISEASE; CALCIUM; MANAGEMENT; MORTALITY;
D O I
10.1016/j.numecd.2010.02.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aim: Elevated serum phosphate and calcium-phosphate levels play an important role in the pathogenesis of vascular calcifications in uraemic patients and appear to be associated with increased cardiovascular mortality. We aimed to evaluate the effects of a partial replacement of food protein with a low-phosphorus and low-potassium whey protein concentrate on phosphate levels of dialysis patients with hyperphosphataemia. Methods and Results: Twenty-seven patients undergoing chronic haemodialysis were studied for a 3-month period. In the intervention group (n = 15), food protein were replaced by 30 or 40 g of low-phosphorus and low-potassium protein concentrate aimed at limiting the phosphate intake. In the control group (n = 12) no changes were made to their usual diet. Anthropometric measurements, biochemical markers and dietary interviews were registered at baseline and during the follow-up period. From baseline to the end of the study, in the intervention group, serum phosphate and circulating intact parathyroid hormone levels lessened significantly (8.3 +/- 1.2 mg/dL vs 5.7 +/- 1.4 mg/dL and 488 +/- 205 pg/ml vs 177 +/- 100 pg/ml respectively; p < 0.05) with decreasing of phosphate and potassium intake. No significant differences were found in the control group. No significant changes were observed in serum albumin, calcium, potassium, Kt/V, body weight and body composition in both the intervention and control groups. Conclusion: Dietary intake of phosphate mainly comes from protein sources, so dietary phosphorus restriction may lead to a protein/energy malnutrition in a dialysis patient. A phosphorus-controlled diet plan including a nutritional substitute resulted in serum phosphate and intact parathyroid hormone decrease without nutritional status modifications in dialysis patients. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:879 / 884
页数:6
相关论文
共 50 条
  • [21] Phosphate binders: Sevelamer in the prevention and treatment of hyperphosphataemia in chronic renal failure
    Spaia, S.
    HIPPOKRATIA, 2011, 15 : 22 - 26
  • [22] DIETARY RESTRICTION OF PHOSPHATE IN RENAL-DISEASE
    BINSWANGER, U
    NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (17): : 974 - 974
  • [23] Real-world safety and effectiveness of sucroferric oxyhydroxide for treatment of hyperphosphataemia in dialysis patients: a prospective observational study
    Vervloet, Marc G.
    Boletis, Ioannis N.
    de Francisco, Angel L. M.
    Kalra, Philip A.
    Ketteler, Markus
    Messa, Piergiorgio
    Stauss-Grabo, Manuela
    Derlet, Anja
    Walpen, Sebastian
    Perrin, Amandine
    Ficociello, Linda H.
    Rottembourg, Jacques
    Wanner, Christoph
    Cannata-Andia, Jorge B.
    Fouque, Denis
    CLINICAL KIDNEY JOURNAL, 2021, 14 (07) : 1770 - 1779
  • [24] The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients
    D'Alessandro, Claudia
    Piccoli, Giorgina B.
    Cupisti, Adamasco
    BMC NEPHROLOGY, 2015, 16
  • [25] The “phosphorus pyramid”: a visual tool for dietary phosphate management in dialysis and CKD patients
    Claudia D’Alessandro
    Giorgina B Piccoli
    Adamasco Cupisti
    BMC Nephrology, 16
  • [26] Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?
    Toussaint, Nigel D.
    Holt, Stephen G.
    NEPHROLOGY, 2017, 22 : 36 - 41
  • [27] Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
    Greig, Sarah L.
    Plosker, Greg L.
    DRUGS, 2015, 75 (05) : 533 - 542
  • [28] Individualize phosphate binder therapy in patients with chronic hyperphosphataemia and renal failure
    Adis Medical Writers
    Drugs & Therapy Perspectives, 2013, 29 (11) : 353 - 357
  • [29] Efficacy of colestilan in the treatment of hyperphosphataemia in renal disease patients
    Locatelli, Francesco
    Dimkovic, Nada
    Spasovski, Goce
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1475 - 1488